KNTE

Kinnate Biopharma Inc. Common Stock

KNTE

Market cap $125M

Delisted

KNTE was delisted on the 2nd of April, 2024.

Back to rankings

About: Kinnate Biopharma Inc is a clinical-stage precision oncology company focused on the discovery, design, and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. The company's pipeline product candidates are; exarafenib (KIN-2787), which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor in development for the treatment of patients with lung cancer, melanoma, and other solid tumors, and KIN-3248, a Fibroblast Growth Factor Receptors (FGFR) inhibitor, designed for the treatment of patients with intrahepatic cholangiocarcinoma (ICC), a cancer of the bile ducts in the liver, and urothelial carcinoma (UC), a cancer of the bladder lining, as well as other solid tumors.

Employees: 27

Healthcare Drug Manufacturers - General

Financial journalist opinion

KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kinnate Biopharma Inc. (NasdaqGS: KNTE) to XOMA Corporation (NasdaqGM: XOMA). Under the terms of the proposed transaction, shareholders of HireRight will receive (i) a base cash price of $2.3352 per share and (ii) an additional cash amount of not more than $0.2527 per share at the closing of the merger plus a.

KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories

Kinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets. The transaction is in furtherance of Kinnate's previously announced pursuit of strategic alternatives.

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories

SAN FRANCISCO, SAN DIEGO and CASTRES, France, March 01, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, and Pierre Fabre Médicament, SAS (“Pierre Fabre Laboratories”), a global player in oncology, today announced their agreement to the sale of the Company's investigational pan-RAF inhibitor, exarafenib, and other pan-RAF program assets pursuant to the APA entered into by the parties. The sale of global rights is in furtherance of the Company's previously announced exploration of strategic alternatives.

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories

Zacks Investment Research

Kinnate Biopharma Inc. (KNTE) Upgraded to Buy: What Does It Mean for the Stock?

Kinnate Biopharma Inc. (KNTE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kinnate Biopharma Inc. (NasdaqGS: KNTE) to XOMA Corporation (NasdaqGM: XOMA). Under the terms of the proposed transaction, shareholders of HireRight will receive (i) a base cash price of $2.3352 per share and (ii) an additional cash amount of not more than $0.2527 per share at the closing of the merger plus a.

KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc.

NEW YORK , Feb. 16, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Kinnate Biopharma Inc. (NASDAQ: KNTE) and its board of directors concerning the proposed acquisition of the company by XOMA Corporation. Stockholders will receive between $2.3352 and $2.5879, as well as one contingent value right, for each share of Kinnate Biopharma stock that they hold.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc.

Shareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMA

MILWAUKEE , Feb. 16, 2024 /PRNewswire/ -- Ademi LLP is investigating Kinnate (Nasdaq: KNTE) for possible breaches of fiduciary duty and other violations of law in its transaction with XOMA. Click here to learn how to join the https://www.ademilaw.com/case/kinnate-biopharma-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMA

KNTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kinnate Biopharma Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Kinnate Biopharma Inc. (NASDAQ: KNTE) to XOMA Corporation is fair to Kinnate shareholders. Under the terms of the proposed transaction, XOMA would acquire Kinnate for (i) a base cash price of $2.3352 per share and (ii) an additional cash amount of not more than $0.2527 per share at the closing of the merger plus a non-transferable contingent value right, representing the right to recei.

KNTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kinnate Biopharma Inc. Is Fair to Shareholders

Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share

SAN FRANCISCO and SAN DIEGO, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, today announced it has entered into a definitive merger agreement (the "Merger Agreement") whereby XOMA Corporation ("XOMA") will acquire Kinnate for a price per share of Kinnate common stock ("Kinnate common stock") of between $2.3352 and $2.5879 in cash, consisting of (i) a base cash price of $2.3352 per share and (ii) an additional cash amount of up to $0.2527 per share, plus one non-transferable contingent value right per share, representing the right to receive (a) 100% of the net proceeds payable from any disposition of the Company's investigational pan-RAF inhibitor, exarafenib, and/or any other pan-RAF inhibitors prior to the closing of the merger transaction and (b) 85% of the net proceeds payable from any disposition of other Kinnate assets entered into prior to, or within one year from, closing and received within five years of closing pursuant to a definitive contingent value rights agreement.

Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share

See News Rankings

Charts implemented using Lightweight Charts™